Quantcast

Latest Prostate cancer Stories

2014-06-11 08:30:52

Inovio Responds to False and Misleading Speculation Regarding Immunotherapy Study BLUE BELL, Pa., June 11, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) wishes to clarify that a third party article published on June 10, 2014, was misrepresentative of facts and can only be taken as malicious. The referenced article does not reflect the progress, status, and potential of Inovio's active immune therapy technology and products and is rife with false and misleading...

2014-06-11 08:29:54

All 9 Out Of 9 Patients Who Have Reached 4 Injections Are Showing Tumor Cell Death, Tumor Shrinkage And/Or Stabilization Of Disease BETHESDA, Md., June 11, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that, in the ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors, all 9 out of 9 patients who have...

2014-06-11 08:29:34

Complete Data to be Submitted for Presentation at the 2014 San Antonio Breast Cancer Symposium REDWOOD CITY, Calif., June 11, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from a second large, independent clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer, also known as DCIS (ductal carcinoma in situ). The study, conducted by the Ontario DCIS Study Group in Canada, met its primary...

2014-06-11 08:28:34

CHESTERBROOK, Pa., June 11, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim(®) (testosterone gel). Prasco has product inventory available and has commenced shipping product. Testim and its Authorized Generic version are testosterone gels approved by the U.S. Food and Drug Administration to treat...

2014-06-10 23:01:05

New recommendations published in JACN emphasize a plant-based diet to reduce the risk of several types of cancer. WASHINGTON, DC (PRWEB) June 10, 2014 Six dietary guidelines – more aggressive than previous cancer prevention advice will be unveiled in the June 30 issue of the Journal of the American College of Nutrition. The cancer prevention guidelines, emphasizing a diet rich in plant-based foods, such as soy beans and cruciferous, allium, and carotenoid vegetables, are based on the...

surgery costs elusive
2014-06-10 10:04:02

Rebekah Eliason for redOrbit.com - Your Universe Online For most products, consumers have access to a wealth of data and information to guide them in a purchasing decision. When it comes to health care, especially the price of surgical procedures, information is nearly impossible to find. According to a new study from the University of Iowa, the quote for prostate cancer surgery varied between 100 hospitals by a 13-fold range. When comparing prices, the team found a wide range of...

2014-06-10 08:29:31

Successful collaboration with AstraZeneca includes two novel cancer drugs in clinical development CARLSBAD, Calif., June 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that AstraZeneca has initiated a Phase 1 clinical study of ISIS-AR(Rx) in patients with cancer. Isis earned a $15 million milestone payment associated with the clinical advancement of ISIS-AR(Rx). ISIS-AR(Rx) is an antisense drug designed to treat patients with prostate cancer by...

2014-06-09 12:31:07

TSX Venture: QPT EDMONTON, June 9, 2014 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, reports today that patient enrollment has been completed in the Company's Phase IIb clinical trial of its lead immunotherapy product candidate Oregovomab for the treatment of Ovarian Cancer. "I am pleased that we have reached this important milestone in our clinical program"...

2014-06-09 12:29:27

LONDON, June 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Japanese Urological Devices Markethttp://www.reportbuyer.com/pharma_healthcare/medical_supplies/hospital_supplies/japanese_urological_devices_market.html In 2012, the Japanese market for urological devices was valued at $411.9 million.This report analyzes the markets for the treatment of benign prostate hyperplasia (BPH), prostate cancer, urinary incontinence as well as urinary and kidney...

2014-06-09 08:28:48

IBA to Manufacture and Supply 89Zr-Df-IAB2M for Multi-Center Studies in the US LOS ANGELES and DULLES, Va., June 9, 2014 /PRNewswire/ -- ImaginAb, Inc. (ImaginAb) and IBA Molecular North America, Inc. (IBA Molecular) announced that IBA Molecular has been selected to provide radiochemistry manufacturing and clinical distribution of (89)Zr-Df-IAB2M, an immunoPET tracer for imaging prostate cancer, to support multi-center clinical studies in the US. IBA Molecular will manufacture...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related